Autologous Anti-Egfr/Anti-Il13Ralpha2 Car T-Cells
Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Recurrent Glioblastoma, IDH-Wildtype cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Mayo Clinic | Phase 2 | B |
Epirubicin Mayo Clinic | Phase 2 | B |
Pembrolizumab Mayo Clinic | Phase 2 | B |
Cerebraca Wafer Everfront Biotech Co., Ltd. | Phase 2/3 | B |
Tiragolumab National Cancer Institute (NCI) | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Autologous Anti-Egfr/Anti-Il13Ralpha2 Car T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →